KardiaAI vs AVIEW
AI Verdict
Choose KardiaAI if…
Choose KardiaAI if your primary need is real-time or ambulatory analysis of ECG rhythms for the immediate detection of various cardiac arrhythmias. This tool is ideal for integrating medical-grade AI into mobile health applications or existing ECG devices to provide precise, automated insights into heart rhythm disorders like AFib, bradycardia, and tachycardia.
View KardiaAI →Choose AVIEW if…
Choose AVIEW if your focus is on comprehensive AI-powered analysis of CT scans for the early detection, diagnosis, and monitoring of lung diseases and cardiovascular conditions. This platform is best suited for radiologists and pulmonologists seeking to enhance diagnostic precision for lung nodules, quantify emphysema, or perform coronary artery calcium scoring, while also streamlining imaging workflows.
View AVIEW →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | KardiaAI | AVIEW |
|---|---|---|
| Pricing | Subscription-based for advanced features and services. | Subscription; one-off payment |
| Deployment | Mobile app, cloud-based. | Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker) |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
KardiaAIKardiaAI's deployment as an API library integrated into mobile apps and web platforms suggests a focus on user-friendly interfaces and accessibility for its specific function of ECG analysis. AVIEW, while offering workflow automation, is a comprehensive radiology platform with 3D visualizations and deep PACS/RIS/CIS integration, which typically implies a more complex professional interface and a steeper learning curve.
Clinical Value
AVIEWBoth tools offer significant clinical value with FDA clearance and medical-grade accuracy. However, AVIEW provides a broader and more comprehensive set of diagnostic and prognostic capabilities across multiple critical conditions (lung cancer, COPD, and coronary artery disease) from CT scans, including detailed characterization (e.g., Lung-RADS scoring) and risk stratification, which offers a wider clinical impact.
Pricing & Value
KardiaAIKardiaAI offers transparent and relatively affordable subscription tiers (e.g., KardiaCare Monthly: $13.99/month), making its pricing clear and accessible for individual users or smaller practices. AVIEW's pricing, based on installations and users with both one-off and subscription options, is typical for enterprise solutions and lacks public transparency, making a direct value comparison difficult without specific quotes.
Enterprise Readiness
AVIEWBoth tools are FDA-cleared and HIPAA compliant, and offer integration capabilities. However, AVIEW demonstrates superior enterprise readiness with its diverse deployment options (cloud, hybrid, local, virtualized) and explicit integration with standard hospital systems like PACS/RIS/CIS, catering to complex IT environments and large-scale radiology workflows.
Innovation
AVIEWWhile KardiaAI innovates by making medical-grade ECG analysis highly accessible through its API and mobile integrations, AVIEW demonstrates a broader and deeper application of AI. Its ability to perform multi-disease detection, detailed characterization (e.g., Lung-RADS, ILD texture analysis), and quantitative scoring for lung cancer, COPD, and coronary artery calcification from a single CT scan represents a more advanced and comprehensive innovative approach in medical imaging AI.
Support & Docs
TieThe provided information does not detail specific support offerings or documentation quality for either tool. As both are established companies with FDA-cleared products, it can be inferred that both provide adequate support and documentation tailored to their respective user bases (consumer/developer for KardiaAI, enterprise for AVIEW).
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | KardiaAI | AVIEW |
|---|---|---|
| Name | KardiaAI | AVIEW |
| Company | AliveCor | Coreline Soft Co. |
| Primary Application Area | Analyzing ambulatory ECG rhythms for detecting various cardiac conditions. | Early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans. |
| Compliance | HIPAA Compliant: Yes, Has BAA: Yes | HIPAA Compliant: Yes, Has BAA: Not specified |
| Target Medical Specialties | Cardiology, Emergency Medicine, Internal Medicine | Cardiology, Pulmonology, Radiology |
| Core AI Detections/Analyses | AI-powered ECG analysis for atrial fibrillation, bradycardia, tachycardia, normal sinus rhythm, PVCs, Wide QRS, SVE; ECG noise filtering. | AI-powered lung nodule detection and characterization, Emphysema quantification, Coronary artery calcium (CAC) scoring, Automated segmentation, 3D visualizations, ILD pattern analysis. |
Videos
Demos, reviews, and walkthroughs featuring KardiaAI and AVIEW.
More Comparisons
More matchups featuring KardiaAI or AVIEW
Backers
Who funded each tool's parent company.